Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Mindset disagrees with and denies the allegations set forth from Reunion.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
To address the preventive & primary healthcare delivery gaps in India
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Subscribe To Our Newsletter & Stay Updated
